Faculty Collaboration Database

Efficacy and safety of sotalol in patients with refractory atrial fibrillation or flutter. Am Heart J 1997 Aug;134(2 Pt 1):155-60

Date

08/01/1997

Pubmed ID

9313591

DOI

10.1016/s0002-8703(97)70118-2

Scopus ID

2-s2.0-0030885578 (requires institutional sign-in at Scopus site)   12 Citations

Abstract

Sotalol's usefulness in treatment of atrial fibrillation and atrial flutter is unproven. This study evaluated (1) the efficacy of sotalol in preventing recurrences of paroxysmal atrial fibrillation or atrial flutter and controlling ventricular rate (in chronic atrial fibrillation or relapse of paroxysmal atrial arrhythmias), (2) the safety of sotalol, and (3) predictors of sotalol efficacy. Thirty-three patients, 28 with paroxysmal and five with chronic atrial fibrillation or atrial flutter, received an average dose of 265 +/- 119 mg of oral sotalol per day. During a 10 +/- 12 month follow-up, recurrence rate for paroxysmal arrhythmia was 64%, with a 50% recurrence at 4.6 months. For patients with chronic atrial fibrillation, ventricular rates were well controlled with sotalol administration (136 +/- 33 beats/min versus 88 +/- 23 beats/min; p = 0.04). No patient with chronic atrial fibrillation converted to sinus rhythm during the study. Side effects necessitated sotalol discontinuation in three patients. By multivariate analysis, younger age, higher ejection fraction, and absence of hypertension independently predicted sotalol efficacy.

Author List

Gallik DM, Kim SG, Ferrick KJ, Roth JA, Fisher JD

Author

James A. Roth MD Associate Professor in the Medicine department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Aged
Atrial Fibrillation
Atrial Flutter
Chronic Disease
Female
Hemodynamics
Humans
Male
Middle Aged
Prospective Studies
Sotalol
Treatment Outcome